Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Damir Boras is active.

Publication


Featured researches published by Damir Boras.


Canadian Journal of Diabetes | 2014

Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals

Lawrence A. Leiter; Damir Boras; Vincent Woo

OBJECTIVE Despite their importance in achieving good glycemic control, few real-world data on insulin dosing irregularities and hypoglycemia are available. The multinational, online Global Attitude of Patients and Physicians (GAPP2) survey was conducted to address this situation. METHODS Insulin-treated patients with type 2 diabetes and healthcare professionals (HCPs) who treat such patients were surveyed in an online cross-sectional study. This article summarizes findings from a sample of the online population in a Canadian cohort of 156 patients and 202 HCPs. RESULTS A total of 156 patients completed the questionnaires; 26% reported experiencing a dosing irregularity (missed, mistimed or reduced a basal insulin dose) in the previous 30 days. Up to 60% reported risk for hypoglycemia as the reason for intentional dosing irregularities. Of all patients, 80% reported experiencing a self-treated hypoglycemic event, and 33% recalled having at least 1 event in the previous month. HCPs recorded similar levels of patient-reported dosing irregularities. Over 90% indicated they recommended patients to temporarily reduce their insulin doses to deal with hypoglycemia. CONCLUSIONS A sizeable minority of patients experienced dosing irregularities and self-treated hypoglycemia in this Canadian cohort. The data suggest that HCPs who completed the survey are aware of this and of the need to provide education and support for patients who regularly miss, mistime or reduce insulin doses. Although the desire to prevent hypoglycemic events is understandable and important, HCPs need to ensure fear of hypoglycemia does not compromise optimal diabetes management.


Canadian Journal of Diabetes | 2017

The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study

Ronnie Aronson; Ronald Goldenberg; Damir Boras; Rasmus Skovgaard; Harpreet S. Bajaj

OBJECTIVE The true prevalence of hypoglycemia in insulin-treated patients with diabetes and its impact on patients, employers and healthcare providers is poorly appreciated owing to a paucity of real-world data. The global Hypoglycemia Assessment Tool (HAT) study addressed this issue, and here we report data from the Canadian cohort of patients. METHODS This noninterventional, 6-month retrospective and 4-week prospective study enrolled patients aged ≥18 years receiving insulin treatment for >12 months from community endocrinology practices. Data were collected using self-assessment questionnaires and patient diaries. The primary endpoint was the proportion of patients experiencing ≥1 hypoglycemic event during the 4-week prospective observational period. RESULTS Four hundred ninety-eight patients with type 1 diabetes (n=183) and type 2 diabetes (n=315) were enrolled. The prevalence of hypoglycemia was similar in the retrospective (type 1 diabetes, 92.3%; type 2 diabetes, 63.5%) and prospective (type 1 diabetes, 95.2%; type 2 diabetes, 64.2%) periods. Prospective rates of any, nocturnal and severe hypoglycemia per patient-year (95% confidence interval) were 69.3 (66.4; 72.2), 14.2 (12.9; 15.6) and 1.8 [1.4; 2.4]. Higher rates were reported retrospectively, reaching significance for nocturnal hypoglycemia per patient-year (30.0 [28.1; 32.0] vs. 14.2 [12.9; 15.6]; p<0.001). Hypoglycemia led to increased healthcare utilization and absenteeism and was associated with potentially harmful self-care behaviours (e.g., reduced or skipped insulin doses) and increased blood glucose self-monitoring. CONCLUSIONS Prevalence and incidence of hypoglycemia were high among insulin-treated patients with diabetes in Canada, and some patients took harmful or costly actions when they experienced hypoglycemia. Identifying the insulin-treated patients who are at greatest risk may help to reduce the incidence of hypoglycemia.


Canadian Journal of Diabetes | 2012

Steady State is Reached within Two to Three Days of Once-daily Administration of Ultra-Long-acting Insulin Degludec

Tim Heise; Leszek Nosek; Hans-Veit Coester; Carsten Roepstorff; Stine Segel; Nathan Lassota; Damir Boras; Hanne Haahr


Canadian Journal of Diabetes | 2012

Insulin Degludec 200 U/mL is Ultra-long Acting and has a Flat and Stable Glucose-lowering Effect

Tim Heise; Leszek Nosek; Ulrike Höevelmann; Susanne G. Bøttcher; Hanne Hastrup-Nielsen; Damir Boras; Hanne Haahr


Canadian Journal of Diabetes | 2015

Liraglutide 3.0 mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity: The SCALE Obesity and Prediabetes Randomised Trial

David C.W. Lau; Michel Krempf; Arne Astrup; Carel W. le Roux; Ken Fujioka; Frank L. Greenway; Alfredo Halpern; Rafael Violante Ortiz; John Wilding; Damir Boras; Søren Kruse Lilleøre; Xavier Pi-Sunyer


Canadian Journal of Diabetes | 2015

Effects of Liraglutide 3.0 mg and 1.8 mg on Body Weight and Cardiometabolic Risk Factors in Adults with Overweight or Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial

Sue Pedersen; Ralph A. DeFronzo; Richard M. Bergenstal; Bruce W. Bode; Robert F. Kushner; Andrew Lewin; Maureen Noctor; Damir Boras; Melanie J. Davies


Canadian Journal of Diabetes | 2015

Liraglutide 3.0 mg Reduces Body Weight and Improves Health-Related Quality of Life (HRQoL) in Overweight or Obese Adults without Diabetes: The SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial

Joanne Liutkus; Ken Fujioka; Arne Astrup; Frank L. Greenway; Alfredo Halpern; Michel Krempf; David C.W. Lau; Carel W. le Roux; Rafael Violante Ortiz; John Wilding; Michael Lyng Wolden; Damir Boras; Xavier Pi-Sunyer


Canadian Journal of Diabetes | 2015

Additional Analyses of the Weight-lowering Efficacy of Liraglutide 3.0 mg in Adults with Overweight and Obesity: The SCALE Obesity and Prediabetes Randomized Trial

David C.W. Lau; Frank L. Greenway; Ken Fujioka; Arne Astrup; Alfredo Halpern; Michel Krempf; Carel W. le Roux; Rafael Violante Ortiz; John Wilding; Søren Kruse Lilleøre; Damir Boras; Xavier Pi-Sunyer


Canadian Journal of Diabetes | 2015

Liraglutide 3.0 mg Reduces Severity of Obstructive Sleep Apnea and Body Weight in Individuals with Obesity and Moderate or Severe Disease: SCALE Sleep Apnoea Trial

Adam Blackman; Gary D. Foster; Gary Zammit; Russell Rosenberg; Thomas A. Wadden; Louis J. Aronne; Morten Donsmark; Damir Boras


Canadian Journal of Diabetes | 2016

Switching from Sitagliptin to Liraglutide in Subjects with Type 2 Diabetes (T2D): Analysis of Composite Endpoints from the LIRA-SWITCH Randomized Trial

Damir Boras; Timothy S. Bailey; Róbert Takács; Francisco J. Tinahones; Paturi V. Rao; George M. Tsoukas; Sidsel B. Christensen; Margit Staum Kaltoft; Maximo Maislos

Collaboration


Dive into the Damir Boras's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Frank L. Greenway

Pennington Biomedical Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arne Astrup

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar

John Wilding

University of Liverpool

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rafael Violante Ortiz

Mexican Social Security Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge